Also found in: Dictionary, Thesaurus, Encyclopedia.
Related to gonococci: gonococcus, meningococci


(gon'ō-kok'sī), Avoid the mispronunciation gon-ō-kok'ī.
Plural of gonococcus.


[gon′əkok′əs] pl. gonococci
Etymology: Gk, gone + kokkos, berry
a gram-negative intracellular diplococcus of the species Neisseria gonorrhoeae, the cause of gonorrhea; a nonmotile aerobic microorganism of the species N. gonorrhoeae. It is a parasite of the mucous membrane.


(gon?o-kok'us) (gon?o-kok'si?) plural.gonococci [Gr. gonos, genitals, + kokkos, berry]
Neisseria gonorrhoeae, the gram-negative diplococcus that causes gonorrhea.
See: gonorrheagonococcal (gon?o-kok'al), adjectivegonococcic (gon?o-kok'sik)
References in periodicals archive ?
In principle, laboratory methods for susceptibility testing of gonococci are similar to those for other bacteria.
By 1958, however, chromosomal resistance to penicillin in gonococci was described although it could be overcome by increased therapeutic dosage.
Since the introduction of tetracycline therapy for the treatment of gonorrhoea and/or chlamydial infection, gonococci that exhibit a low level of resistance to this drug have been isolated with increasing frequency.
12) In addition, gonococci can employ both the MacA-MacB and MtrC-MtrD-MtrE ABC efflux systems to become resistant to macrolides.
Many gonococci with higher MICs, in the region of 2 mg/l or above, were found to have mutations in both the gyrA and parC genes.
20) In central Japan, significant rises in gonococci exhibiting decreased susceptibility to penicillin, fluoroquinolones, tetracycline and oral cephalosporins have been observed since 2001.
22) Sequencing the penA gene in gonococci exhibiting reduced susceptibility to cefixime revealed a mosaic-like structure of PBP-2, in which some regions showed homology to penA genes in N.
gonorrhoeae strains, these latter agents may treat any gonorrhoea present even if the gonococci are resistant to ciprofloxacin.
Construction of isogenic gonococci with variable porin structure--effects on susceptibility to human serum and antibiotics.
avium, malaria, atypical bacteria such as Legionella, Mycoplasma, Chlamydophila, and against gonococci.
The carrier protein selected by the Company for its meningococcal conjugate vaccine products has the potential to elicit antibodies that may impede this mechanism for meningococci and gonococci bacterial infections.